

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS


IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : C12Q 1/68, C12P 19/34 C07H 15/12	A1	(11) International Publication Number: WO 93/22461 (43) International Publication Date: 11 November 1993 (11.11.93)
(21) International Application Number: PCT/US93/04015 (22) International Filing Date: 29 April 1993 (29.04.93) (30) Priority data: 07/879,686 6 May 1992 (06.05.92) US (71) Applicant: GEN-PROBE INCORPORATED [US/US]; 9880 Campus Point Drive, San Diego, CA 92121 (US). (72) Inventors: KACIAN, Daniel, Louis ; 3911 Tambor Road, San Diego, CA 92124 (US). McALLISTER, Diane, Lisa ; 8664 Anrol Avenue, San Diego, CA 92123 (US). McDONOUGH, Sherrol, Hoffa ; 4697 Robbins Street, San Diego, CA 92122 (US). DATTA GUPTA, Nanib- hushan ; 4221 Kerwood Court, San Diego, CA 92130 (US).		(74) Agents: WARBURG, Richard, J. et al.; Lyon & Lyon, 611 West Sixth Street, 34th Floor, Los Angeles, CA 90017 (US). (81) Designated States: AU, CA, FI, JP, KR, NO. Published <i>With international search report.</i>
(54) Title: NUCLEIC ACID SEQUENCE AMPLIFICATION METHOD, COMPOSITION AND KIT		

**(57) Abstract**

A method, composition and kit for amplifying a target nucleic acid sequence under conditions of substantially constant temperature, ionic strength, and pH and using only a single promoter-primer. To effect the amplification, a supply of a single promoter-primer having a promoter and a primer complementary to the 3'-end of the target sequence, and a reserve transcriptase and an RNA polymerase are provided to a mixture including the target sequence; the amplification proceeds accordingly. The invention is useful for generating copies of a nucleic acid target sequence for purposes that include assays to quantitate specific nucleic acid sequences in clinical, environmental, forensic and similar samples, cloning and generating probes.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LI	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

1.

DESCRIPTIONNucleic Acid Sequence AmplificationMethod, Composition and KitField of the Invention

The field of the present invention is increasing the number of copies (or amplifying) of a specific nucleic acid sequence or "target sequence." The target sequence
5 may be present either alone or as a component, large or small, of an homogeneous or heterogeneous mixture of nucleic acids. The mixture of nucleic acids may be that found in a sample taken for diagnostic testing, environmental testing, for research studies, for the preparation
10 of reagents or materials for other processes such as cloning, or for other purposes.

The selective amplification of specific nucleic acid sequences is of value in increasing the sensitivity of diagnostic and environmental assays, and other uses, while
15 maintaining specificity, increasing the sensitivity, convenience, accuracy and reliability of a variety of research procedures, and providing ample supplies of specific oligonucleotides for various purposes.

The present invention is particularly suitable for
20 use in environmental and diagnostic testing due to the convenience with which it may be practiced.

Background of the Invention

The detection and/or quantitation of specific nucleic acid sequences is an increasingly important technique for
25 identifying and classifying microorganisms, diagnosing infectious diseases, detecting and characterizing genetic abnormalities, identifying genetic changes associated with cancer, studying genetic susceptibility to disease, and measuring response to various types of treatment. Such
30 procedures have also found expanding uses in detecting and quantitating microorganisms in foodstuffs, environmental

samples, seed stocks, and other types of material where the presence of specific microorganisms may need to be monitored. Other applications are found in the forensic sciences, anthropology, archaeology, and biology where measurement of the relatedness of nucleic acid sequences has been used to identify criminal suspects, resolve paternity disputes, construct genealogical and phylogenetic trees, and aid in classifying a variety of life forms.

10 A common method for detecting and quantitating specific nucleic acid sequences is nucleic acid hybridization. This method is based on the ability of two nucleic acid strands which contain complementary or essentially complementary sequences to specifically
15 associate, under appropriate conditions, to form a double-stranded structure. To detect and/or quantitate a specific nucleic acid sequence (known as the "target sequence"), a labelled oligonucleotide (known as a "probe") is prepared which contains sequences comple-
20 mentary to those of the target sequence. In a process commonly known as "screening," the probe is mixed with a sample suspected of containing the target sequence, and conditions suitable for hybrid formation are created. The probe hybridizes to the target sequence if it is present
25 in the sample. The probe-target hybrids are then separated from the single-stranded probe in one of a variety of ways. The amount of label associated with the hybrids is then measured as an indication of the amount of target sequence in the sample.

30 The sensitivity of nucleic acid hybridization assays is limited primarily by the specific activity of the probe, the rate and extent of the hybridization reaction, the performance of the method for separating hybridized and unhybridized probe, and the sensitivity with which the
35 label can be detected. Under the best conditions, direct hybridization methods such as those described above can detect about 1×10^5 to 1×10^6 target molecules. However,

the most sensitive procedures may lack many of the features required for routine clinical and environmental testing such as speed, convenience, and economy. Furthermore, the sensitivities of even the most sensitive
5 procedures may not be sufficient for many desired applications.

As a result of the interactions among the various components, and the component steps of this type of assay, there is almost always an inverse relationship between
10 sensitivity and specificity. Thus, steps taken to increase the sensitivity of the assay (such as increasing the specific activity of the probe) may result in a higher percentage of false positive test results. The linkage between sensitivity and specificity has been a significant
15 barrier to improving the sensitivity of hybridization assays. One solution to this problem would be to specifically increase the amount of target sequence present using an amplification procedure. Amplifying a unique portion of the target sequence without amplifying a
20 significant portion of the information encoded in the remaining sequences of the sample could give an effective increase in sensitivity while at the same time not compromising specificity.

A method for specifically amplifying nucleic acid
25 sequences termed the "polymerase chain reaction" or "PCR" has been described by Mullis, et al. (See U.S. patents 4,683,195, 4,683,202 and 4,800,159 and European patent applications 86302298.4, 86302299.2, and 87300203.4 and Methods in Enzymology, Volume 155, 1987, pp. 335-350).
30 The PCR procedure uses repeated cycles of primer dependent nucleic acid synthesis occurring simultaneously using each strand of a complementary sequence as a template. In the PCR procedure, copies of both strands of a complementary sequence are synthesized. In order to make the PCR
35 convenient, programmable thermal cycling instruments are required.

The PCR procedure has been coupled to RNA transcription by incorporating a promoter sequence into one of the primers used in the PCR reaction and then, after amplification by the PCR procedure for several cycles, using the double-stranded DNA as template for the transcription of single-stranded RNA. (See, e.g., Murakawa et al., DNA 7:287-295 (1988)).

Other methods for amplification of a specific nucleic acid sequence comprise a series of cycles of primer hybridization, extending steps and denaturing steps to provide an intermediate double stranded DNA molecule containing a promoter sequence through the use of a promoter sequence-containing primer. The double stranded DNA is used to produce multiple RNA copies of the target sequence. The resulting RNA copies can be used as target sequences to produce further copies and multiple cycles can be performed. (See, e.g., Burg, et al., WO 89/1050; Gingeras, et al., WO 88/10315 (sometimes called "transcription amplification system" or TAS); EPO Application No. 89313154 to Kacian and Fultz; EPO Application No. 88113948.9 to Davey and Malek; Malek, et al. WO91/02818).

Walker, et al., Proc. Natl. Acad. Sci. (USA) 89:392-396 (Jan. 1992), not admitted to be prior art, describes an oligonucleotide driven amplification method for use with a DNA template, using a restriction endonuclease to produce the initial target sequences and an enzyme to nick the DNA/DNA complex in order to enable an extension reaction and therefore amplification. Becker, et al., EPO Application No. 88306717.5, describes an amplification method in which a primer is hybridized to the target sequence and the resulting duplex is cleaved prior to the extension reaction and amplification; in the case where the primer extends past the region of hybridization, it requires cleavage prior to the extension and the primer must be blocked at its 3'-end to prevent any unwanted extension reactions from occurring prior to amplification.

Kramer, et al., U.S. Patent No. 4,786,600 describe a method of producing large numbers of copies of a probe sequence in an RNA target sequence using Q β replicase. Urdea, WO 91/10746, describes a signal amplification
5 method that incorporates a T7 promoter sequence.

Other methods of amplifying nucleic acid include the ligase chain reaction (LCR), described in European Patent Publication 320,308, in which at least four separate oligoprobes are used; two of the oligoprobes hybridize to
10 opposite ends of the same target strand in appropriate orientation such that the third and fourth oligoprobes may hybridize with the first and second oligoprobes to form, upon ligation, connected probes that can be denatured and detected. Another method is that described in EPO
15 Publication No. 0 427 073 A2, published May 15, 1991 and not admitted to be prior art, in which a palindromic probe able to form a hairpin and having a functional promoter region in the hairpin is hybridized to a target sequence, then ligated to a second oligonucleotide hybridized to the
20 target sequence such that RNA transcripts may be made.

Still other methods include oligonucleotide synthesis and cloning.

Summary of the Invention

The present invention is directed to synthesizing
25 multiple copies of a target nucleic acid sequence without the need to modify reaction conditions such as temperature, pH, or ionic strength, and without the need to add multiple, different primers or promoters, nor enzymes other than polymerases, which may also have RNase H
30 activities.

The present invention may be used as a component of assays to detect and/or quantitate specific nucleic acid target sequences in clinical, environmental, forensic, and similar samples or to produce large numbers of copies of
35 DNA and/or RNA of specific target sequence for a variety of uses. The present invention may also be used to produce multiple DNA or RNA copies of a nucleic acid

target sequence for cloning or to generate probes or to produce RNA or DNA copies for sequencing.

The present method features incubating a mixture consisting essentially of a nucleic acid target sequence (DNA or RNA) with one or more oligonucleotides known as "promoter-primers" that have a "complexing" sequence (i.e., a primer) sufficiently complementary to the 3'-end of a target sequence to hybridize at or near the 3'-end of the target sequence. The promoter-primer also includes, located 5' to the complexing sequence, a promoter for an RNA polymerase.

By "at or near" is simply meant to indicate the 3'-end of the target itself, and not necessarily the whole RNA or DNA-molecule which is to be detected. For example, the "target" may be a small central portion of an RNA molecule within an otherwise large RNA molecule.

By "one or more" it is meant that the promoter-primers added to the reaction mixture are sufficiently similar that they are able to bind to approximately the same target sequence at approximately the same position (plus or minus about 10 bases, on the same strand) such that the amplification of the instant invention may go forward. This does not exclude providing other oligonucleotides to the mixture, for example "helper" oligonucleotides that aid hybridization of the promoter-primers.

By "consisting essentially of" as used above, it is meant that the mixture has all of the necessary reactants and reagents. However, such a mixture may also contain enzymes or other substituents that do not qualitatively affect the amplification of the invention, and the mixture may contain other promoter-primers for the same target sequence or "helper" oligonucleotides. A "helper" oligonucleotide is a nucleic acid sequence that assists complexing between the promoter-primer, or other complexing nucleic acid such as a probe, and the target sequence, and will be determined by the actual sequence at the 3'-

end of the target sequence. Such helper oligonucleotides are used in a manner equivalent to hybridization helper oligonucleotides described by Hogan et al., U.S. Patent 5,030,557, namely by aiding binding of the promoter-primer to its target nucleic acid even if that target nucleic acid has significant secondary structure. Despite the similarity in use of such helper oligonucleotides it is surprising that such helper oligonucleotides could be used in an amplification protocol without adverse effect on the efficiency of these procedures.

The promoter-primer and the target sequence are subjected to conditions whereby a promoter-primer/target sequence hybrid is formed and DNA synthesis can be initiated. It is believed that in this reaction, the 3'-end of the target sequence is extended in a DNA extension reaction from a location adjacent the hybridized complex between the complexing sequence and the target sequence. The promoter sequence is the template for this extension reaction, which produces a first DNA extension product and thereby a double stranded promoter sequence. The 3'-end of the promoter-primer may also serve as a primer, for a second DNA extension reaction, which reaction uses the target sequence as a template and results in a double stranded nucleic acid complex; the complex is a DNA/RNA complex if an RNA target sequence is used, and a DNA/DNA complex if a DNA target sequence is used.

The first DNA extension product is then used by an RNA polymerase that recognizes the promoter of the promoter-primer, to produce multiple RNA copies of the target sequence. Surprisingly, in the case of an RNA/DNA complex or RNA alone comprising the target sequence, a DNA-dependent RNA polymerase, such as T7 RNA polymerase, is able to "read" the RNA/DNA complex or RNA and produce single stranded RNA, and is therefore effective in the present invention.

In preferred embodiments, the promoter-primer has a modification that may comprise a modified nucleotide at or

near its 3'-end that inhibits or prohibits nucleic acid extension in that direction. It is surprising that the invention may be performed with the 3'-end of the promoter-primer modified, and it is particularly surprising that using a mixture of a modified and an unmodified promoter-primer (or two differently modified promoter-primers) results in a higher efficiency amplification, and therefore a higher copy number, than use of an unmodified or modified promoter-primer alone. Methods for creating such useful modifications to prevent or decrease primer extension are known in the art.

Where the target sequence comprises DNA or RNA, a further aspect of the present invention includes generation of a 3'-end of the target sequence by chemical or enzymatic degradation or processing, so that extension of the 3'-end of the target sequence along the promoter region of the promoter-primer may proceed. Such generation may be performed by, for example, the action of RNase H on an RNA:DNA hybrid (e.g., a DNA promoter-primer and an RNA target hybrid), treatment with exonucleases, and digestion with specific restriction endonucleases (e.g., for a DNA target) or ribozymes (e.g., with an RNA or DNA target).

In other preferred embodiments, the present invention features inclusion of one or more "helper" oligonucleotides in the reaction composition.

In yet other preferred embodiments, the 5'-end of the target strand of nucleic acid may be defined so as to stop either the extension reaction or the transcription reaction. Methods to effect such definition are known in the art and may include complexing an appropriate sequence of nucleic acid (e.g., an oligonucleotide) to the 5'-end of the target sequence, or modification of the 5'-end of the target sequence.

The present invention also features a composition consisting essentially of a target sequence, a promoter-primer, an RNA polymerase, a DNA polymerase and/or a

reverse transcriptase and reagent and buffer conditions sufficient to allow amplification. In another embodiment, the promoter-primer includes both modified and unmodified 3'-ends. The invention also features a composition including a mixture of modified and unmodified promoter-primers and/or a mixture of different promoter-primers suitable for use in this invention.

In one example of a typical assay featuring the present invention, a sample of target nucleic acid to be amplified is mixed with a buffer concentrate containing appropriate buffer, salts, magnesium, nucleotide triphosphates, one or more promoter-primers, dithiothreitol, and spermidine. The reaction is then optionally incubated near 100°C to denature any secondary structure. (This step is unnecessary if the target is single-stranded RNA, and the promoter-primer is also single-stranded.) After cooling to room temperature, reverse transcriptase and RNA polymerase are added and the reaction is incubated for a time span from minutes to hours at a suitable constant temperature between, e.g., 37°C to 42°C, at which the enzymes are active. The reaction can then be assayed by adding a probe solution, incubating 10-30 minutes at 60°C, adding a solution to selectively hydrolyze the unhybridized probe, incubating the reaction for 5-10 minutes at 60°C, and measuring the remaining chemiluminescence in a luminometer, as described by Arnold, et al., PCT US88/02746, the disclosure of which is incorporated herein by reference, and is referred to as the "HPA" method. The products of the methods of the present invention may be used in many other assay systems, or for other uses, known to those skilled in the art.

The present invention further features a kit that incorporates the components of the invention and makes possible convenient performance of the invention. Such a kit may also include other materials that would make the invention a part of other procedures, and may also be adaptable for multi-well technology.

Definitions

As used herein, the following terms have the following meanings unless expressly stated to the contrary.

A. Nucleic Acid.

- 5 "Nucleic acid" means either RNA or DNA, along with any nucleotide analogues or other molecules that may be present in the sequence and that do not prevent performance of the present invention.

B. Template.

- 10 A "template" is a nucleic acid molecule that is able to be copied by a nucleic acid polymerase. A template may be either RNA or DNA, and may be any of single-stranded, double-stranded or partially double-stranded, depending on the polymerase. The synthesized copy is complementary to
15 the template.

C. Primer.

- A "primer" is an oligonucleotide that is sufficiently complementary to a template so that it hybridizes (by hydrogen bonding or hybridization under hybridizing conditions, e.g., stringent conditions) with the template to
20 give a primer/template complex suitable for initiation of synthesis by a DNA polymerase, such as a reverse transcriptase, and which is extended by the addition of covalently bonded bases linked to its 3' end that are
25 complementary to the template. The result is a primer extension product. Virtually all DNA polymerases (including reverse transcriptases) that are known require complexing of an oligonucleotide to a single-stranded template ("priming") to initiate DNA synthesis. Under
30 appropriate circumstances, a primer may be a part of a promoter-primer. Such primers are generally between 10 and 100 bases in length, preferably between 20 and 50 bases in length.

D. Promoter or Promoter Sequence.

A "promoter" or "promoter sequence" is a specific nucleic acid sequence that is recognized by a DNA-dependent RNA polymerase ("transcriptase") as a signal to bind to a nucleic acid molecule and begin the transcription of RNA at a specific site. For binding, such transcriptases generally require that the promoter and its complement be double-stranded; the template portion need not be double-stranded. Individual DNA-dependent RNA polymerases recognize a variety of different promoter sequences that can vary markedly in their efficiency of promoting transcription. When an RNA polymerase binds to a promoter sequence to initiate transcription, that promoter sequence is not part of the sequence transcribed. Thus, the RNA transcripts produced thereby will not include the promoter sequence.

E. Promoter-primer.

A promoter-primer comprises a promoter and a primer. It is an oligonucleotide that is sufficiently complementary to the 3'-end of a target nucleic acid sequence to complex at or near the 3'-end of that target nucleic acid sequence, which means that the promoter-primer complexes near enough to the end of the target sequence to allow amplification of enough of the target sequence that the requirements of the assay, testing, cloning or other use for the amplified nucleic acid are met. The promoter-primer is used as a template to create a complementary nucleic acid sequence extending from the 3'-end (also known as the 3' terminus) of a target nucleic acid sequence, to result in a generally double stranded promoter, subject to any denaturing or enzymatic activity that may disrupt the double strand.

A DNA- or RNA-dependent DNA polymerase also creates a complementary strand to the target nucleic acid molecule, using as a template the portion of the target

sequence 5' to the complementary region of the promoter-primer.

The 3'-end of the promoter-primer may be modified, or blocked, so as to prohibit or inhibit an extension reaction from proceeding therefrom. A solution of promoter-primer comprising both modified and unmodified promoter-primer consists of essentially the same nucleic acid sequence for the purposes of the present invention. The modified promoter-primer does not contain a different promoter nor a different recognition sequence from the unmodified promoter-primer. This means that, within about 10 bases, the modified and unmodified promoter-primers are recognized by the same RNA polymerase, and recognize the same target sequence (although not necessarily at precisely the same position). In a preferred embodiment, the modified and unmodified or mixture of modified promoter-primers are identical except for the modification. The 3'-end of the promoter-primer can be blocked in a variety of ways well known to those skilled in the art. Such promoter-primers are generally between 40 and 100 bases in length, preferably between 40 and 60 bases.

F. Target Nucleic Acid Sequence, Target Sequence.

A "target nucleic acid sequence," or "target sequence," has a desired nucleic acid sequence to be amplified, and may be either single-stranded or double-stranded and may include other sequences beside 5' or 3' of the sequences to be amplified which may or may not be amplified.

The target nucleic acid sequence includes the complexing sequences to which the promoter-primer hybridizes during performance of the present invention. Where the target nucleic acid sequence is originally single-stranded, the term refers to either the (+) or (-) strand, and will also refer to the sequence complementary to the target sequence. Where the target nucleic acid

sequence is originally double-stranded, the term refers to both the (+) and (-) strands.

G. Plus (+) and Minus (-) Strand(s).

Discussions of nucleic acid synthesis are greatly
5 simplified and clarified by adopting terms to name the two
complementary strands of a nucleic acid duplex. Traditionally, the strand encoding the sequences used to produce proteins or structural RNAs was designated as the "plus" strand and its complement the "minus" strand. It
10 is now known that in many cases, both strands are functional, and the assignment of the designation "plus" to one and "minus" to the other must then be arbitrary. Nevertheless, the terms are very useful for designating the sequence orientation of nucleic acids and will be
15 employed herein for that purpose, with the "plus" strand denominating the original target sequence strand that is complexed with the promoter-primer.

H. DNA-Dependent DNA Polymerase.

A "DNA-dependent DNA polymerase" is an enzyme that
20 synthesizes a complementary DNA copy from a DNA template. Examples are DNA polymerase I from E. coli and bacteriophage T7 DNA polymerase. All known DNA-dependent DNA polymerases require a complementary primer to initiate synthesis. It is known that under suitable conditions
25 certain DNA-dependent DNA polymerases may synthesize a complementary DNA copy from an RNA template.

I. DNA-Dependent RNA Polymerase (Transcriptase).

A "DNA-dependent RNA polymerase" or "transcriptase"
is an enzyme that synthesizes multiple RNA copies from a
30 double-stranded or partially-double stranded DNA molecule having a (usually double-stranded) promoter sequence. It should be noted that the present invention includes single stranded promoters, along with the RNA polymerases that recognize them. The RNA molecules ("transcripts") are

synthesized in the 5' → 3' direction of the RNA molecule, beginning at a specific position just downstream of the promoter. Examples of transcriptases are the DNA-dependent RNA polymerases from E. coli and bacteriophages T7, T3, and SP6. Under appropriate conditions, as shown herein, some transcriptases may use RNA or an RNA:DNA copolymer as a template.

J. RNA-Dependent DNA Polymerase (Reverse Transcriptase).

10 An "RNA-dependent DNA polymerase" or "reverse transcriptase" is an enzyme that synthesizes a complementary DNA copy from an RNA template. All known reverse transcriptases also have the ability to make a complementary DNA copy from a DNA template; thus, they are both RNA- and
15 DNA-dependent DNA polymerases. A primer is required to initiate synthesis with either the RNA or DNA templates.

K. RNase H.

An "RNase H" is an enzyme that degrades the RNA portion of an RNA:DNA duplex. RNase H's may be endo-
20 nucleases or exonucleases. Most reverse transcriptase enzymes normally contain an RNase H activity in addition to their polymerase activity. However, other sources of the RNase H are available without an associated polymerase activity. The degradation may result in separation of RNA
25 from a RNA:DNA complex. Alternatively, the RNase H may simply cut the RNA at various locations such that portions of the RNA melt off or permit enzymes to unwind portions of the RNA, or the RNA fragments generated may serve as primers for a DNA polymerase.

30 L. Hybridize, Complex.

The terms "hybridize" and "complex" refer to the formation of duplexes between nucleotide sequences that are sufficiently complementary to form duplexes (or "complexes") via Watson-Crick base pairing. Where a

promoter-primer or primer "hybridizes" with target (template), such complexes (or hybrids) are sufficiently stable to serve the priming function required by a DNA polymerase to initiate DNA synthesis.

5 M. Modified Primer or Promoter-primer.

 The 3'-end of the primer or promoter-primer may be modified, or blocked, so as to prohibit or inhibit an extension reaction from proceeding therefrom. A primer or promoter-primer having both modified and unmodified
10 members consists of essentially the same nucleic acid sequence for the purposes of the present invention. In other words, the modified primer or promoter-primer does not contain a different complexing sequence (primer) in terms of its specificity in that both the modified and
15 unmodified oligonucleotide hybridizes in effectively the same position (plus or minus about ten bases) on the target nucleic acid sequence such that amplification of the target sequence is not prohibited. Also, the modified promoter-primer does not contain a different recognition
20 sequence (promoter) from the unmodified promoter-primer. This means that, within about 10 bases, the modified and unmodified primers or promoter-primers are the same, are recognized by the same RNA polymerase, and recognize the same target sequence (although not necessarily at
25 precisely the same position). In a preferred embodiment, the modified and unmodified primers or promoter-primers are identical except for the modification.

 The 3'-end of the primer or promoter-primer can be modified in a variety of ways well known to those skilled
30 in the art. Appropriate modifications to a promoter-primer can include addition of ribonucleotides, 3' deoxynucleotide residues, (e.g., cordycepin (CO, Glen Research)), 3',2'-dideoxy nucleotide residues, modified nucleotides such as phosphorothioates, and non-nucleotide
35 linkages such as described in Arnold, et al., (PCT US 88/03173) (RS) or alkane-diol modifications (Wilk et al.

Nuc. Acids Res. 18:2065, 1990) (RP), or the modification may simply consist of a region 3' to the priming sequence that is uncomplementary to the target nucleic acid. Of course, other effective modifications are possible as well.

A mixture of modified and unmodified oligonucleotides may be used in an amplification reaction, and ratios of blocked to unblocked oligonucleotide from 2:1 to 1,000:1 have been successfully used. A mixture of oligonucleotides with different 3' modifications may also be used.

Brief Description of the Drawings

Figure 1 depicts a promoter-primer and a target nucleic acid that has a defined 3'-end and, thus, no additional sequences 3' to the target sequence, but which does have additional sequences 5' to the target sequence.

Figure 2 depicts an RNA target sequence having additional sequences 3' to the complexing region of the target sequence.

Figure 3 is a diagrammatic representation of an alkane diol modification or RP, on an oligonucleotide (zigzag line).

Detailed Description of the Invention

The present invention is directed to a method, composition and kit for the amplification of specific nucleic acid target sequences. Such amplified target sequences are useful in assays for the detection and/or quantitation of specific nucleic acid target sequences or for the production of large numbers of copies of DNA and/or RNA of specific target sequences for a variety of uses.

Using Fig. 1 for illustration, the present invention features a method comprising treating a nucleic acid target sequence 2, which may be RNA or DNA, with an oligonucleotide 4 that comprises a promoter-primer that has a promoter 6 and a primer 8, wherein the primer 8 is

sufficiently complementary to the 3'-end 9 portion of the target sequence to complex at or near the 3'-end 9 of the target sequence. The promoter-primer 4 consists essentially of only a single nucleic acid sequence, and no other promoter-primers need be introduced to the reaction mixture to achieve amplification. Promoters suitable for the promoter-primer of the present invention are nucleic acid sequences (produced naturally, synthetically or as a product of a restriction digest) that are specifically recognized by an RNA polymerase that binds to that sequence and initiates the process of transcription whereby RNA transcripts are produced. The promoter sequence may optionally include nucleotide bases extending beyond the actual recognition site for the RNA polymerase, which may impart added stability or susceptibility to degradation processes or increased transcription efficiency. Promoter sequences for which there is a known and available polymerase are particularly suitable. Such promoters include those recognized by RNA polymerases from bacteriophages T3, T7 or SP6, or from E. coli.

In some circumstances it may be desirable to introduce "helper" oligonucleotides into the mixture, which helper oligonucleotides assist the promoter-primer to complex with the target sequence.

The promoter-primer 4 and the target sequence 2 are subjected to conditions whereby a promoter-primer/target sequence complex 11 is formed and DNA synthesis may be initiated. Accordingly, the reaction mixture is incubated under conditions whereby a promoter-primer/target sequence complex is formed, including DNA priming and nucleic acid synthesizing conditions (including ribonucleotide triphosphates and deoxyribonucleotide triphosphates) for a period of time sufficient whereby multiple copies of the target sequence are produced. The reaction advantageously takes place under conditions suitable for maintaining the stability of reaction components such as the component enzymes and without requiring modification or manipulation

of reaction conditions during the course of the amplification reaction. Accordingly, the reaction may take place under conditions that are substantially isothermal and include substantially constant ionic strength and pH. In other words, the reaction conditions may be effectively constant, which means that the temperature, pH and ionic concentration are not significantly, purposefully altered so as to affect the reaction conditions. The components of the reaction mixture may be combined stepwise or at once.

During performance of the reaction, the 3'-end of the target sequence is extended by an appropriate DNA polymerase in an extension reaction using the promoter sequence of the promoter-primer as a template to give a DNA extension product complementary to the promoter sequence. The 3'-end of the primer region of the promoter-primer is also extended in an extension reaction, using an appropriate reverse transcriptase, to form a complementary strand to the target nucleic acid sequence. The resulting double stranded promoter is then used to bind the appropriate RNA polymerase, which then uses the resulting double stranded target nucleic acid sequence to produce multiple copies of single stranded RNA (which will be complementary to the (+) strand of the target sequence).

The DNA polymerase for extension of the promoter-primer must be an RNA-dependent DNA polymerase (i.e., a reverse transcriptase) when the target sequence is RNA. Concomitantly, where the target sequence comprises DNA, the DNA polymerase must be a DNA-dependent DNA polymerase. However, as all known reverse transcriptases also possess DNA-dependent DNA polymerase activity, it is not necessary to add a DNA-dependent DNA polymerase other than reverse transcriptase in order to perform the extension reaction, including where the promoter-primer is DNA and the target sequence is RNA. Suitable reverse transcriptases include AMV reverse transcriptase and MMLV reverse transcriptase.

The RNA polymerase required for the present invention may be a DNA-dependent RNA polymerase, such as the RNA polymerases from E. coli and bacteriophages T7, T3 and SP6; it is surprising that such a DNA-dependent RNA
5 polymerase is effective when the target sequence is RNA.

In the case where the target sequence is DNA, the 3'-end of the target sequence must be defined, as in Fig. 1, to coincide approximately with the 5'-end of the primer of the primer-promoter (i.e., the target sequence must not
10 have nucleotides extending 3' past the region complexed with the primer). Of course, such generation may also be practiced on an RNA target nucleic acid sequence. Generation of such a defined 3'-end of the nucleic acid target by chemical or enzymatic degradation or processing
15 are known in the art.

As depicted in Fig. 2, the amplification may surprisingly be performed on an RNA target sequence 14 that has a strand of nucleotides 16 extending 3' past region 11 complexed with the primer.

20 It is a feature of the present invention that multiple copies of either DNA or RNA may be obtained.

In a preferred embodiment, the promoter-primer has a modification at its 3'-end to prevent or decrease extension from that end (along the target sequence). Methods
25 of producing such modifications are known in the art. It is surprising that the amplification may be performed with the 3'-end so modified, and also surprising that using a mixture of modified and unmodified promoter-primer will result in higher efficiency amplification. For example,
30 a ratio of about 150 modified promoter-primers to 1 unmodified promoter-primer has been found to greatly increase the efficiency and effectiveness of amplification. However, this ratio will change according to the reaction conditions and reagents, such as the promoter-
35 primer and the target sequence.

In still a further aspect, the invention features a kit comprising some or all of the reagents, enzymes and

promoter-primers necessary to perform the invention. The items comprising the kit may be supplied in separate vials or may be mixed together, where appropriate.

Examples

5 Preface

The following examples demonstrate the mechanism and utility of the present invention. They are not limiting and should not be considered as such.

The enzymes used in the following examples are avian
10 myeloblastosis virus (AMV) reverse transcriptase, T7 RNA polymerase, Moloney murine leukemia virus (MMLV) reverse transcriptase, and Superscript (RNase H minus MMLV RT, "MMLV SC RT") from Bethesda Research Laboratories. Other enzymes containing similar activities and enzymes from
15 other sources may be used. Other RNA polymerases with different promoter specificities may also be suitable for use.

Unless otherwise specified, the reaction conditions used in the following examples were 50 mM Tris-HCl, pH
20 7.6, 25 mM KCl, 17.5 mM MgCl₂, 5 mM dithiothreitol, 2 mM spermidine trihydrochloride, 6.5 mM rATP, 2.5 mM rCTP, 6.5 mM rGTP, 2.5 mM rUTP, 0.2 mM dATP, 0.2 mM dCTP, 0.2 mM dGTP, 0.2 mM dTTP, 0.3 μ M promoter-primer, 600 units of MMLV reverse transcriptase and 400 units of T7 RNA poly-
25 merase, and specified amounts of template in 100 μ l volumes. However, the best reaction conditions will vary according to the requirements of a given use and circumstances; given the present disclosure, such conditions will be apparent to one skilled in the art. The oligo-
30 nucleotide sequences used are exemplary and are not limiting as other sequences have been employed for these and other target sequences.

Example 1.

To demonstrate the invention using a target sequence
35 with a defined 3'-end, a promoter-primer (Seq. ID No. 1)

21

containing a sequence complementary to the 3' end of Ureaplasma urealyticum 5S rRNA, was incubated with RNA in the presence of T7 RNA polymerase and MMLV reverse transcriptase for four hours. Samples of the reaction were removed at certain timepoints and analyzed by hybridization with two probes of the same sense as the target RNA (Seq ID Nos. 2, 3) in the presence of helper probes (Seq ID Nos. 4, 5) as described in Hogan (U.S. Patent 5,030,557, Means for Enhancing Nucleic Acid Hybridization).

	Time of incubation		RLU
	1 fmole target	0.1 fmole target	
	15 min	5,389	307
	30 min	10,360	778
15	60 min	40,622	5,588
	120 min	144,851	13,051
	180 min	192,618	16,249
	240 min	203,393	20,745

Example 2.

To demonstrate that the invention works with a target sequence containing nucleotides 3' to the promoter-primer binding site, a promoter-primer containing sequences complementary to 21 bases of Streptococcus pneumoniae 16S rRNA corresponding to bases 683-703 of the E. coli reference sequence, (Seq ID No. 6), was incubated with 1 fmole of (+) sense S. pneumoniae rRNA in the presence of the following enzymes. Ten μ l of the reaction was assayed with acridinium ester labelled probes of both senses (Seq ID No. 7), with helper probes (Seq ID No. 8, 9), or their complements. In a separate experiment, part of the reaction was hydrolyzed with NaOH prior to hybridization.

22

Enzymes	(+) sense probe	(-) sense probe
MMLV RT + T7	434,463	7,333
MMLV SC RT + T7	2,617	3,579
MMLV RT, no T7	2,614	1,733
5 MMLV RT + T7, no primer	1,753	3,840
MMLV RT + T7, no NaOH	615,299	
MMLV RT + T7, + NaOH	2,499	

The results show that the amplification of the present invention is dependent on reverse transcriptase, T7 RNA polymerase and RNase H activity, and that the predominant product produced is RNA complementary to the target RNA.

Example 3.

To determine if extension of the 3' end of the promoter-primer was required for amplification, a promoter-primer was synthesized with 3' modifications using standard chemistry, as described by Arnold et al. (RS; PCT US. 88/03173) or Wilk, et al., (RP; Figure 3 in Nucleic Acids Res. 18:2065, 1990), or cordycepin (CO, Glen Research). The effect of these modifications on extension by reverse transcriptase was tested in the following experiment. A promoter-primer with a sequence complementary to S. pneumoniae 16S rRNA (Seq ID 6) was hybridized to target, then incubated in the presence of MMLV RT for 30 min. At the end of the extension reaction, the RNA and cDNA was denatured at 95°C for two minutes, and assayed by hybridization protection assay with a probe the same sense as the rRNA (Seq ID No. 7) with helper probes (Seq ID Nos. 8, 9).

23

		RLU	
Amount of target:		1 pmole	0 pmole
Primer:			
unmodified		756,996	5,038
5	3' RSL	391,079	4,132
	3' RP	68,153	4,365
	3' CO	10,521	4,717

The results indicated that the 3' modifications did alter extension by reverse transcriptase relative to the unmodified primer.

Example 4.

To determine if extension of the 3' end was required for the amplification of a target sequence with a defined 3'-end, the promoter-primer complementary to the 3' end of Ureaplasma urealyticum 5S rRNA (Seq. ID 1), was modified at the 3' end with RS, and incubated with 1 fmole of target RNA, MMLV reverse transcriptase and T7 RNA polymerase. Hybridization with probes as described in Example 1 indicated that efficient extension of the promoter-primer was not required for amplification. Reverse transcriptase activity was required, as shown by the lack of amplification in the reaction containing only T7 RNA polymerase.

Enzymes		RLU	
		unmodified	modified
25	MMLV RT + T7	11,189	12,443
	MMLV SC RT + T7	8,738	3,742
	T7 only	1,838	1,694
	No target	1,272	1,157

Example 5.

To test the effect of 3' modifications on amplification of a target containing sequences 3' to the promoter-primer binding site, a promoter-primer containing sequences complementary to S. pneumoniae 16S rRNA, (Seq ID

No. 6), was synthesized with 3' RS, 3' RP, or 3' cordy-
 cepin modification. The modified and unmodified promoter-
 primers were incubated with *S. pneumoniae* rRNA, MMLV
 reverse transcriptase and T7 RNA polymerase at 37°C for 4
 5 hr. Ten μ l of the reaction was assayed with a probe of
 the same sense as the target RNA.

		RLU		
Primer		1 fmol target	0.1 fmol target	0 target
unmodified		39,652	7,952	2,785
10	3' RSL	227,639	15,732	3,117
	3' RP	556,708	589,168	3,368
	3' CO	509,262	30,004	3,219

Surprisingly, the data show that modifications to the
 3' end of the promoter-primer increased the signal
 15 observed with this amplification mechanism.

Example 6.

The following experiment was performed to demonstrate
 the kinetics of accumulation of product with promoter-
 primers with unmodified or modified 3' ends. A promoter-
 20 primer containing sequences complementary to *M.*
tuberculosis 23S rRNA was incubated with 1 fmole of *M.*
tuberculosis rRNA in the presence of MMLV RT and T7 RNA
 polymerase. At the time points indicated, samples were
 removed and assayed with an acridinium ester labelled
 25 probe the same sense as the target RNA. Background RLU
 from target free reactions were subtracted from the data.

Time		Unmodified	3' RS	3' RP
0 min		0	0	0
15 min		2,266	430	43
30	30 min	7,622	1,532	214
	60 min	9,349	9,584	1,403
	120 min	15,281	32,007	150,781
	180 min	24,528	38,086	590,033
	240 min	23,866	46,276	868,145

The data show that the unmodified and 3' RS modified promoter-primers accumulate product in a linear manner, while the 3' RP promoter-primer appears to accumulate product in a more exponential fashion. This result was also unexpected, and implies a unique amplification mechanism that occurs at essentially constant temperature, pH and ionic strength.

Example 7.

In this example, different promoter-primers were incubated with S. pneumoniae rRNA for 4 hours in the presence of 600 units of AMV reverse transcriptase and 400 units of T7 RNA polymerase. Ten μ l of sample were assayed with an acridinium-ester labeled probe of the same sense as the target RNA.

15		1fmol target	0fmol target
	Unmodified	66,042	3,607
	3' RP	359,597	3,411
	3' CO	110,260	2,984

The data show that the 3' modified promoter-primers result in higher signals than the unmodified version with AMV reverse transcriptase.

Example 8.

The following experiment demonstrated that additives (DMSO and glycerol) increase the effectiveness (sensitivity) of the amplification system. Modified or unmodified promoter-primers (Seq ID No. 6) were added to S. pneumoniae rRNA in the presence of MMLV reverse transcriptase and T7 RNA polymerase and incubated at 37°C for 4 hours. Ten μ l of reaction were assayed with acridinium ester labelled probe of the same sense as the target RNA, and negative values were subtracted.

26

Primer	DMSO/gly	0.1 fmol	0.01 fmol
unmodified	-	3,176	18
	+	1,468	763
3' CO	-	5,168	668
5 3' RP	+	46,915	3,070
	-	83,870	7,400
	+	935,945	117,051

The data show that the additives had little effect on the results with the unmodified promoter-primer, but increased signals significantly with the 3' modified promoter-primers, with the most marked effect with the 3' RP version.

Example 9.

In this experiment, promoter-primers with a sequence complementary to the 23S rRNA of M. tuberculosis, (Seq ID No. 10) were synthesized with one (ribo) or two (diriibo) 3' terminal deoxycytidines replaced with one or two 3' ribocytidine residues, or with a 3' terminal phosphorothioate (PS) deoxynucleotide. These modified promoter-primers were used to amplify M. tuberculosis rRNA in 50 mM Tris HCl pH 8, 20 mM MgCl₂, 35 mM KCl, 4 mM each GTP, ATP, UTP, CTP and 1 mM each dTTP, dGTP, dCTP, dATP, 15 mM N-acetyl-cysteine, 10 % glycerol, 10% DMSO, 600 units MMLV reverse transcriptase, and 400 units T7 RNA polymerase, at 42°C for 4 hours. Five µl of each reaction was heated to 95°C for 2 minutes and assayed with a probe of the same sense as the rRNA target (Seq ID # 11), with helper probes ID 12 and 13.

27

	Tmol Target:	3,000	300	30	3	0
	Primer					
	Unmodified	11,162	1,508	931	779	807
	3' RP	1,901,532	1,494,050	513,419	14,243	658
5	3' ribo	57,401	3,992	644	670	589
	3'diribo	34,265	11,459	1,445	666	584
	Unmodified		1,799	877	N.T.	782
	3'PS		266,755	12,567	1,617	656

The results showed that promoter-primers with one or
 10 two ribonucleotides at the 3' end, or with a 3' phosphoro-
 thioate linkage, give better amplification in this system
 than unmodified promoter-primers.

Example 10.

Another method for altering the extension of
 15 promoter-primer by reverse transcriptase was to mix
 unmodified promoter-primer with blocked, cordycepin-
 modified promoter-primer. Use of a mixture of promoter-
 primers would significantly decrease the production of
 cDNA observed in a reverse transcription reaction, as
 20 observed for other 3' modifications. The following
 experiment used promoter-primers with sequence comple-
 mentary to M. tuberculosis 16S rRNA (Seq ID.# 14), either
 modified with cordycepin or unmodified. The promoter-
 primers were incubated with 3 tmol of M. tuberculosis
 25 rRNA, 300 units of MMLV reverse transcriptase and 200
 units of T7 RNA polymerase, using the same conditions as
 example 9 except that 10 mM trimethyl ammonium chloride
 was present. After a 2 hour incubation at 42 °C, twenty
 µl of the reaction was assayed with a probe of the same
 30 sense as the target RNA (Seq ID 15, with helpers #16, 17).
 The results are the average of 5 replicates.

	Target	3'CO Primer	Unmodified Primer	RLU
	+	15 pmol	0 pmol	1,879
	+	14.9 pmol	0.1 pmol	191,988
35	-	15 pmol	0 pmol	1,055

As can be seen, a mixture of modified and unmodified promoter primer worked better than completely modified promoter primer. Varying the ratio (e.g., between 1:1 to 150:1) of modified to unmodified promoter-primer effectively increased the efficiency of amplification. The optimal ratio will change according to reaction conditions, including the reagents used, the target sequence, and the promoter-primer. Selecting appropriate conditions for a given amplification is within the skill of one skilled in the art without undue experimentation.

In a separate experiment, the signals obtained from the amplification were compared to known standards, and the degree of amplification calculated to be 2.6×10^5 fold.

15 Example 11.

In this example, reactions were performed as in Example 10, except that the promoter primers were unmodified or modified with RP or CO. Thirty μ mol target was added to each reaction. As shown, a mixture of promoter primers with different 3' modifications result in significant amplification.

Primer			RLU
3' CO	3' RP	Unmodified	
15 pmol	--	0.1 pmol	802,374
25 13 pmol	2 pmol	--	440,854

The amount of non-specific product generated was shown to be much lower with the modified primers, evidencing another advantage of the invention.

Example 12.

30 The increase in the number of complementary copies of the target sequence with time requires reverse transcript-

ase and T7 RNA polymerase. When the promoter-primer hybridizes to the 3' end of a target, copying of the T7 promoter sequence results in a double-stranded DNA promoter that can be recognized by T7 RNA polymerase and
 5 utilized to make RNA copies of the target sequence. The results with the 3' modified promoter-primers implied that the T7 RNA polymerase was using RNA as a template for RNA synthesis. Synthetic oligonucleotides were made to test this hypothesis. The first oligonucleotide was a DNA
 10 promoter-primer, containing a 5' T7 promoter sequence linked to a 3' target binding sequence. Another oligonucleotide containing only the promoter sequence was also synthesized. The target sequence consisted of an RNA:DNA chimeric molecule containing 5' synthetic RNA target
 15 sequence with the DNA complement of the T7 promoter sequence attached to the 3' end.

In this experiment the 10 or 1 fmol of the RNA-DNA chimeric target was hybridized with the promoter-primer containing the T7 promoter and a target binding sequence,
 20 or the promoter sequence alone, leaving the RNA target strand single-stranded. The hybrids were incubated with or without T7 RNA polymerase and the products were hybridized with a probe of the same sense as the RNA target sequence.

25 Promoter-primer	RLU			
	10 fmol		1fmol	
	+ T7	-T7	+T7	-T7
Pro+target	146,060	2,490	16,532	2,721
pro only	425,127	2,753	33,474	2,557

30 Surprisingly, the data show that an RNA fragment can be used by T7 RNA polymerase as a template for RNA transcription.

Example 13.

The following experiment showed that an RNA strand
 35 can be used to synthesize RNA in the presence of reverse

transcriptase and T7 RNA polymerase. In this experiment, the RNA:DNA chimeric target was compared to a synthetic RNA fragment containing only the target sequence.

Target	T7	RT	10 fmole	1 fmole
5 RNA:DNA chimera	+	MMLV	1,369,888	264,864
	+	AMV	334,139	118,406
	-	-	5,066	
RNA target	+	MMLV	13,609	3,875
	+	AMV	26,318	4,824
10	-	-	5,862	

The present embodiments of this invention are to be considered in all respects as illustrative and not restrictive, the scope of the invention being indicated by the appended claims rather than by the foregoing description, and all changes which come within the meaning and range of equivalency of the claims therefore are intended to be embraced therein.

(1) GENERAL INFORMATION:

- (i) APPLICANT: Daniel L. Kacian
Diane L. McAllister
Sherrol H. McDonough
Nani Bhushan Dattagupta
- (ii) TITLE OF INVENTION: NUCLEIC ACID SEQUENCE
AMPLIFICATION METHOD,
COMPOSITION AND KIT
- (iii) NUMBER OF SEQUENCES: 17
- (iv) CORRESPONDENCE ADDRESS:
- (A) ADDRESSEE: Lyon & Lyon
(B) STREET: 611 West Sixth Street
(C) CITY: Los Angeles
(D) STATE: California
(E) COUNTRY: USA
(F) ZIP: 90017
- (v) COMPUTER READABLE FORM:

31

- (A) MEDIUM TYPE: 3.5" Diskette, 1.44 Mb storage
- (B) COMPUTER: IBM compatible
- (C) OPERATING
- 5 SYSTEM: IBM P.C. DOS (Version 5.0)
- (D) SOFTWARE: WordPerfect (Version 5.1)
- (vi) CURRENT APPLICATION DATA:
- (A) APPLICATION NUMBER:
- (B) FILING DATE:
- 10 (C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
- Prior applications total,
including application
described below: none
- 15 (A) APPLICATION NUMBER:
- (B) FILING DATE:
- (viii) ATTORNEY/AGENT INFORMATION:
- (A) NAME: Warburg, Richard J.
- (B) REGISTRATION NUMBER: 32,327
- 20 (C) REFERENCE/DOCKET NUMBER:
- (ix) TELECOMMUNICATION INFORMATION:
- (A) TELEPHONE: (213) 489-1600
- (B) TELEFAX: (213) 955-0440
- (C) TELEX: 67-3510
- 25 (2) INFORMATION FOR SEQ ID NO: 1:
- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 53
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- 30 (D) TOPOLOGY: linear
- (ii) SEQUENCE DESCRIPTION : SEQ ID NO: 1:
- AATTTAATAC GACTCACTAT AGGGAGAGCG TAGCGATGAC CTATTTTACT
TGC 53
- (2) INFORMATION FOR SEQ ID NO: 2:
- 35 (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 30
- (B) TYPE: nucleic acid

SUBSTITUTE SHEET

32

(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 2:
CGAACACAGA AGTCAAGCAC TCTAGAGCCG 30

5 (3) INFORMATION FOR SEQ ID NO: 3:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 36
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
10 (D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 3:
GTGATCATAT CAGAGTGGAA ATACCTGTTC CCATCC 36

(4) INFORMATION FOR SEQ ID NO: 4:

(i) SEQUENCE CHARACTERISTICS:

15 (A) LENGTH: 34
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 4:
20 GTAGTGATCA TATCAGAGTG GAAATACCTG TTCC 34

(5) INFORMATION FOR SEQ ID NO: 5:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 26
(B) TYPE: nucleic acid
25 (C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 5:
GCAAGTAAAA TAGGTCATCG CTACGC 26

(6) INFORMATION FOR SEQ ID NO: 6:

30 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 48
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

35 (ii) SEQUENCE DESCRIPTION : SEQ ID NO: 6:
AATTTAATAC GACTCACTAT AGGGAGACTA CGCATTTCAC CGCTACAC 48

33

(7) INFORMATION FOR SEQ ID NO: 7:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 22
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 7:

GGCTTAACCA TAGTAGGCTT TG 22

(8) INFORMATION FOR SEQ ID NO: 8:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 39
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 8:

GAGCGCAGGC GGTTAGATAA GTCTGAAGTT AAAGGCTGT 39

(9) INFORMATION FOR SEQ ID NO: 9:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 36
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 9:

GAAACTGTTT AACTTGAGTG CAAGAGGGGA GAGTGG 36

(10) INFORMATION FOR SEQ ID NO: 10:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 47
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 10:

AATTTAATAC GACTCACTAT AGGGAGACCA GGCCACTTCC GCTAACC 47

(11) INFORMATION FOR SEQ ID NO: 11:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 23
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single

SUBSTITUTE SHEET

34

- (D) TOPOLOGY: linear
- (ii) SEQUENCE DESCRIPTION : SEQ ID NO: 7:
GGAGGATATG TCTCAGCGCT ACC 23
- (12) INFORMATION FOR SEQ ID NO: 12:
- 5 (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 38
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear
- 10 (ii) SEQUENCE DESCRIPTION : SEQ ID NO: 12:
CGGCTGAGAG GCAGTACAGA AAGTGTCGTG GTTAGCGG 38
- (13) INFORMATION FOR SEQ ID NO: 13:
- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 36
- 15 (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear
- (ii) SEQUENCE DESCRIPTION : SEQ ID NO: 13:
GGGTAACCGG GTAGGGGTTG TGTGTGCGGG GTTGTG 36
- 20 (14) INFORMATION FOR SEQ ID NO: 14:
- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 55
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- 25 (D) TOPOLOGY: linear
- (ii) SEQUENCE DESCRIPTION : SEQ ID NO: 14:
GAAATTAATA CGACTCACTA TAGGGAGACC ACAGCCGTCA CCCCACCAAC
AAGCT 55
- (15) INFORMATION FOR SEQ ID NO: 15:
- 30 (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 24
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear
- 35 (ii) SEQUENCE DESCRIPTION : SEQ ID NO: 15:
GTCTTGTGGT GGAAAGCGCT TTAG 24
- (16) INFORMATION FOR SEQ ID NO: 16:

SUBSTITUTE SHEET

35

(i) SEQUENCE CHARACTERISTICS:

5 (A) LENGTH: 23
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 16:

CCGGATAGGA CCACGGGATG CAT 23

(17) INFORMATION FOR SEQ ID NO: 17:

(i) SEQUENCE CHARACTERISTICS:

10 (A) LENGTH: 20
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) SEQUENCE DESCRIPTION : SEQ ID NO: 17:

15 CGGTGTGGGA TGACCCCGCG 20

Claims

1. A method of amplifying a ribonucleic acid sequence comprising:
incubating a mixture consisting essentially of:
 - 5 a target nucleic acid sequence consisting essentially of RNA, and
 - one or more promoter-primers consisting essentially of a single nucleic acid sequence comprising a promoter recognizable by an RNA polymerase and a primer located 3' relative to said promoter, said primer being able to complex at or near a 3'-end of said target ribonucleic acid sequence, and
 - 10 a DNA polymerase and said RNA polymerase, at a temperature and in a solution effective to allow amplification of said target ribonucleic acid sequence.
2. The method of claim 1 wherein said DNA polymerase is a reverse transcriptase.
3. The method of claim 1 or 2 wherein said incubation is at essentially constant temperature.
4. The method of claim 1 or 2 wherein at least one of said one or more promoter-primers is a modified promoter-primer comprising a modified nucleotide at its 3'-end to prevent or decrease a nucleic acid extension reaction from proceeding therefrom.
5. The method of claim 4 wherein said one or more promoter-primers comprise modified promoter-primers and unmodified promoter-primers in a ratio effective to produce amplification.
6. The method of claim 4 wherein said one or more promoter-primer comprises modified promoter-primer and

unmodified promoter-primer in a ratio of between about 150:1 and 1:1, respectively.

7. The method of claim 4 wherein said one or more promoter-primers have been modified by addition of one or
5 more ribonucleotides, by addition of a 3' terminal phosphorothioate deoxynucleotide, or by 3'-RS, 3'-alkane-diol residue, or by addition of a 3'-cordycepin.

8. The method of claim 5 wherein said one or more promoter-primers have been modified by addition of one or
10 more ribonucleotides, by addition of a 3' terminal phosphorothioate deoxynucleotide, or by 3'-RS, 3'-alkane-diol residue, or by addition of a 3'-cordycepin.

9. The method of claim 6 wherein said one or more promoter-primers have been modified by addition of one or
15 more ribonucleotides, by addition of a 3' terminal phosphorothioate deoxynucleotide, or by 3'-RS, 3'-alkane-diol residue, or by addition of a 3'-cordycepin.

10. The method of claim 1 or 2 wherein said mixture and said promoter-primer are contacted together prior to
20 addition of said DNA polymerase and said RNA polymerase.

11. The method of claim 1 or 2 wherein said solution further comprises RNase H activity.

12. The method of claim 1 or 2 wherein said solution further comprises an agent to create a definition
25 at a 5'-end of said target nucleic acid sequence such that an extension reaction involving said target nucleic acid sequence will stop at said definition.

13. The method of claim 12 wherein said agent comprises a defining nucleic acid sequence sufficiently
30 complementary to said 5'-end of said target nucleic acid

sequence to be able to complex with said 5'-end of said target nucleic acid sequence at said temperature and in said solution.

14. The method of claim 1 or 2 wherein said target
5 nucleic acid sequence comprises nucleotides at its 3'-end that are not within said complex formed between said target sequence and said promoter-primer.

15. The method of claim 1 or 2 wherein said 3'-end
10 of said target nucleic acid sequence is generated by chemical or enzymatic degradation or processing.

16. The method of claim 15 wherein said chemical or enzymatic degradation or processing comprises treatment with an exonuclease.

17. The method of claim 2 wherein said mixture
15 comprises unmodified promoter-primer and said reverse transcriptase is AMV or MMLV reverse transcriptase.

18. The method of claim 2 wherein said mixture comprises modified promoter-primer and said reverse transcriptase is AMV or MMLV reverse transcriptase.

20 19. The method of claim 2 wherein said mixture comprises both unmodified promoter-primer and modified promoter-primer and said reverse transcriptase is AMV or MMLV reverse transcriptase.

20. The method of claim 18 or 19 wherein said
25 modified promoter-primer comprises a 3' terminal phosphorothioate deoxynucleotide, 3'-RS, 3'-alkane-diol residue, or a 3'-cordycepin.

21. The method of claim 1 or 2 wherein said mixture comprises both modified promoter-primers and unmodified

promoter-primers and said incubation results in at least a 50,000 fold increase of a strand of nucleic acid complementary to or of the same sense as said target nucleic acid sequence.

5 22. The method of claim 1 or 2 wherein said composition further comprises one or more helper oligonucleotides.

 23. The method of claim 1 or 2 wherein said RNA polymerase is a DNA-dependent RNA polymerase.

10 24. The method of claim 23 wherein said DNA-dependent RNA polymerase is selected from the group consisting of T7 RNA polymerase, T3 RNA polymerase and SP6 RNA polymerase.

 25. The method of claim 1 or 2 wherein said composition is screened by hybridization with a probe after
15 said incubation.

 26. A method of amplifying a target ribonucleic acid sequence comprising:

 incubating a mixture consisting essentially of:

20 said target ribonucleic acid sequence, and
 a supply of a single promoter-primer consisting essentially of a single nucleic acid sequence comprising a promoter recognizable by an RNA polymerase and a primer located 3' relative to said promoter, said primer able to
25 hybridize at or near a 3'-end of said target ribonucleic acid sequence, said supply comprising both modified promoter-primer and unmodified promoter-primer in a ratio effective to produce greater amplification compared to said modified or unmodified promoter primer alone, and
30 a reverse transcriptase and said RNA polymerase,
 at a temperature and in a solution effective to allow amplification of said target nucleic acid sequence,

said conditions comprising constant temperature during said amplification.

27. The method of claim 26 wherein said solution further comprises an agent able to define a 5'-end of said target ribonucleic acid sequence such that any extension reaction involving said target nucleic acid sequence will stop at said definition.

28. The method of claim 26 wherein said target ribonucleic acid sequence comprises nucleotides at its 3'-end that are not within said complex formed by said target sequence and said promoter-primer.

29. The method of claim 26 wherein said reverse transcriptase is AMV or MMLV reverse transcriptase.

30. The method of claim 26 or 29 wherein said modified promoter-primer is a 3' terminal phosphorothioate deoxynucleotide, 3'-RS, 3'-alkane-diol residue, or a 3'-cordycepin.

31. The method of claim 26 wherein said composition further comprises one or more helper oligonucleotides.

32. A method for amplifying a ribonucleic acid, comprising the step of:

contacting the ribonucleic acid with a plurality of promoter-primers consisting essentially of a single nucleic acid sequence comprising a promoter recognizable by an RNA polymerase and a primer located 3' relative to said promoter, said primer being able to complex at or near a 3'-end of said target ribonucleic acid sequence, and wherein at least one of said promoter-primers is an unmodified promoter-primer and one is a modified promoter-primer comprising a modified nucleotide at its 3'-end to prevent or decrease a nucleic acid extension reaction from

proceeding therefrom under conditions effective to allow said amplifying.

33. A composition comprising:

a target ribonucleic acid sequence, and

5 one or more promoter-primers consisting essentially of a single nucleic acid sequence comprising a promoter recognizable by an RNA polymerase and a primer located 3' relative to said promoter, said primer being able to complex at or near a 3'-end of said target ribonucleic acid
10 sequence, and wherein at least one of said one or more promoter-primers is a modified promoter-primer comprising a modified nucleotide at its 3'-end to prevent or decrease a nucleic acid extension reaction from proceeding therefrom,

15 a reverse transcriptase,

an RNA polymerase specific for said promoter, and

a solution of reagents able to allow amplification at essentially constant temperature of said composition.

34. The method of claim 33 wherein said one or more
20 promoter-primers comprise modified promoter-primers and unmodified promoter-primers in a ratio effective to produce amplification.

35. The method of claim 33 wherein said one or more promoter-primer comprises modified promoter-primer and
25 unmodified promoter-primer in a ratio of between about 1:1 and 150:1, respectively.

36. The method of claim 33, 34 or 35 wherein said one or more promoter-primers have been modified by addition of one or more ribonucleotides, by addition of a 3'
30 terminal phosphorothioate deoxynucleotide, or by 3'-RS, 3'-alkane-diol residue, or a 3'-cordycepin.

37. The composition of claim 33 further comprising a defining nucleic acid sequence sufficiently complementary to said 5'-end of said target nucleic acid sequence to be able to complex with said 5'-end of said target nucleic acid sequence at said temperature and in said solution.

38. The composition of claim 33 wherein said target nucleic acid sequence comprises nucleotides at its 3'-end that are not within said complex formed between said target sequence and said promoter-primer.

39. The composition of claim 33 wherein said reverse transcriptase is AMV or MMLV reverse transcriptase.

40. The composition of claim 39 wherein said modified promoter-primer comprises a 3'-alkane-diol residue.

41. The composition of claim 33 further comprising one or more helper oligonucleotides.

42. The composition of claim 33 wherein said RNA polymerase is selected from the group consisting of T7 RNA polymerase, T3 RNA polymerase and SP6 RNA polymerase.

43. A kit comprising:

(a) one or more promoter-primers consisting essentially of a single nucleic acid sequence comprising a promoter recognizable by an RNA polymerase and a primer located 3' relative to said promoter, said primer being able to complex at or near a 3'-end of said target ribonucleic acid sequence, said one or more promoter-primers comprising both modified promoter-primers and unmodified promoter-primers in a ratio effective to produce amplification,

(b) a DNA polymerase, and

(c) an RNA polymerase specific for said promoter.

43

44. The kit of claim 43 wherein said one or more promoter-primers are 3' RP modified.

45. The kit of claim 43 wherein said one or more promoter-primers comprise a 3' terminal phosphorothioate deoxynucleotide, 3'-RS, 3'-alkane-diol residue, or a 3'-cordycepin.

46. The kit of claim 43 wherein said DNA polymerase is a reverse transcriptase.

47. The kit of claim 46 wherein said reverse transcriptase is AMV reverse transcriptase or MMLV reverse transcriptase.

48. The kit of claim 43 wherein said RNA Polymerase is a DNA-dependent RNA polymerase from bacteriophages T7, T3 or SP6.

49. The kit of claim 43 further comprising one or more helper oligonucleotides.

50. The kit of claim 43 further comprising a probe suitable for an assay.

51. A kit comprising:

- (a) one or more promoter-primers consisting essentially of a single nucleic acid sequence comprising a promoter recognizable by an RNA polymerase and a primer located 3' relative to said promoter, said primer being able to complex at or near a 3'-end of said target ribonucleic acid sequence, said one or more promoter-primers comprising both modified promoter-primers and unmodified promoter-primers in a ratio effective to produce amplification,
- (b) a reverse transcriptase,
- (c) an RNA polymerase specific for said promoter,

- (d) a solution comprising the reagents necessary to effect amplification without effective alteration of pH, ionic strength or temperature of a combination comprising said solution, said one or more promoter-primers, said
5 reverse transcriptase, and said RNA polymerase,
(e) one or more helper oligonucleotides, and
(f) a probe suitable for an assay.

52. The kit of claim 51 wherein said modified and unmodified promoter-primer are present in a ratio of
10 between 1:1 and 150:1, respectively.

53. The kit of claim 51 wherein said reverse transcriptase is AMV or MMLV reverse transcriptase and said modified promoter-primer is 3' RP modified.

54. The kit of claim 51 wherein said reverse tran-
15 scriptase is AMV or MMLV reverse transcriptase and said modified promoter-primer comprises a 3' terminal phosphorothioate deoxynucleotide, 3'-RS, 3'-alkane-diol residue, or a 3'-cordycepin.

55. A kit comprising
20 a plurality of promoter-primers each consisting essentially of a single nucleic acid sequence comprising a promoter recognizable by an RNA polymerase and a primer located 3' relative to said promoter, said primer being able to complex at or near a 3'-end of said target ribo-
25 nucleic acid sequence, and wherein at least one of said promoter-primers is a first modified or an unmodified promoter-primer, and one is a second modified promoter-primer; wherein said first and second modified promoter-primers comprise a modified nucleotide at their 3'-ends to
30 prevent or decrease a nucleic acid extension reaction from proceeding therefrom under conditions effective to allow said amplifying and said modified nucleotide is different in said first and second promoter-primer.

45

56. Nucleic acid consisting essentially of a sequence chosen from Seq. ID Nos. 1-17.

57. The method of claim 1 wherein said incubating is performed in the presence of one or more of DMSO and
5 glycerol.




Fig. 1




Fig. 2




Fig. 3

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US93/04015

A. CLASSIFICATION OF SUBJECT MATTER IPC(5) : C12Q 1/68; C12P 19/34; C07H 15/12 US CL : 435/6, 91: 536/24.33 According to International Patent Classification (IPC) or to both national classification and IPC																								
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) U.S. : 435/6, 91: 536/24.33 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Please See Extra Sheet.																								
C. DOCUMENTS CONSIDERED TO BE RELEVANT																								
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.																						
Y	EP, A2, 0,408,295 (Kacian et al), 16 January 1991, pages 10 and 11, figures 1C, 1L and 1N.	1-55, 57																						
Y	Proceedings of the National Academy of Sciences, USA, Volume 86, issued December 1989, J. A. Sorge et al, "ExoMeth Sequencing of DNA: Eliminating the Need for Subcloning and Oligonucleotide Primers", pages 9208-9212, especially figure 1.	15, 16																						
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.																								
<table border="0"><tr><td>* Special categories of cited documents:</td><td>*T</td><td>later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td></tr><tr><td>*A</td><td>document defining the general state of the art which is not considered to be part of particular relevance</td><td></td></tr><tr><td>*E</td><td>earlier document published on or after the international filing date</td><td>*X</td><td>document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td></tr><tr><td>*L</td><td>document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td><td>*Y</td><td>document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td></tr><tr><td>*O</td><td>document referring to an oral disclosure, use, exhibition or other means</td><td></td><td></td></tr><tr><td>*P</td><td>document published prior to the international filing date but later than the priority date claimed</td><td>*&</td><td>document member of the same patent family</td></tr></table>			* Special categories of cited documents:	*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	*A	document defining the general state of the art which is not considered to be part of particular relevance		*E	earlier document published on or after the international filing date	*X	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	*L	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Y	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	*O	document referring to an oral disclosure, use, exhibition or other means			*P	document published prior to the international filing date but later than the priority date claimed	*&	document member of the same patent family
* Special categories of cited documents:	*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention																						
*A	document defining the general state of the art which is not considered to be part of particular relevance																							
*E	earlier document published on or after the international filing date	*X	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone																					
*L	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Y	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art																					
*O	document referring to an oral disclosure, use, exhibition or other means																							
*P	document published prior to the international filing date but later than the priority date claimed	*&	document member of the same patent family																					
Date of the actual completion of the international search 16 JUNE 1993		Date of mailing of the international search report 24 JUL 1993																						
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. NOT APPLICABLE		Authorized officer CARLA MYERS Telephone No. (703) 308-0196																						

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US93/04015

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Nucleic Acids Research, Volume 18, NO. 8, issued 1990, A. Wilk et al, "Backbone-Modified Oligonucleotides Containing a Butanediol-1,3, Moiety as a 'Vicarious Segment' for the Deoxyribosyl Moiety-Synthesis and Enzyme Studies", pages 2065-2068, especially page 2065.	7-9,20,21, 30,31,36,40,45,53,54
Y	US, A, 5,030,557 (Hogan) 09 July 1991, especially columns 6 and 7.	22,31,41,49 51-54
Y	PCR Methods and Applications, Volume 1, issued August 1991, E. Fahy et al, "Self-Sustained Sequence Replication (3SR): An Isothermal Transcription-Based Amplification System Alternative to PCR", pages 25-33, especially page 29.	57
Y	WO, 88/03957 (Hogan et al) 02 June 1988, pages 9, 10.	56
Y	Analytical Biochemistry, Volume 201, issued 1992, Hentosh et al, "Polymerase Chain Reaction Amplification of Single-Stranded DNA Containing a Base Analog, 2-Chloroadenine", pages 277-281, see entire document.	1-55, 57

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US93/04015

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

APS; DIALOG - MEDLINE, BIOSIS, CA, WORLD PATENTS

search terms: isothermal in vitro amplification, self-sustained sequence amplification, 3SR, transcription based amplification, TAS blocked 3' terminus, T7 RNA polymerase